This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS (REMMYDYS)

This study has been completed.
Information provided by (Responsible Party):
Dr. Rena Buckstein, Sunnybrook Health Sciences Centre Identifier:
First received: August 29, 2008
Last updated: June 8, 2017
Last verified: June 2017
Angiogenesis increases in higher risk MDS patients and those with proliferative CMML. Angiogenesis is associated with increased risk of leukemic transformation and poorer prognoses. Low dose chemotherapy may have anti-angiogenic properties by targetting the genetically stable endothelial cells. Lenalidomide has been recently shown to be highly effective as monotherapy in low/low-intermediate risk MDS, particularly in the subgroup harboring a 5q- deletion. Lenalidomide has not been well studied in higher risk MDS although there are some reports of lenalidomide's efficacy in RAEB-T and AML. One potential mode of action of lenalidomide is inhibition of angiogenesis. The investigators hypothesize that by combining lenalidomide with low dose melphalan in higher risk MDS the investigators will more effectively block angiogenesis and achieve responses or hematologic improvement in MDS.

Condition Intervention Phase
Myelodysplastic Syndromes Leukemia, Myelomonocytic, Chronic Angiogenesis Drug: Lenalidomide and melphalan Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Revlimid®, and Metronomic Melphalan in the Management of Higher Risk Myelodysplastic Syndromes (MDS) and CMML: A Phase 2 Study"

Resource links provided by NLM:

Further study details as provided by Dr. Rena Buckstein, Sunnybrook Health Sciences Centre:

Primary Outcome Measures:
  • Overall Response Rate (RR) (as defined by modified international working group standardized response criteria) [ Time Frame: 3 years ]
    Overall Response Rate (RR) (as defined by modified international working group standardized response criteria).

Secondary Outcome Measures:
  • Percent with hematologic improvement [ Time Frame: 3 years ]
    Percent with hematologic improvement.

  • Percent with cytogenetic remission [ Time Frame: 3 years ]
    Percent with cytogenetic remission.

  • Overall, progression-free and leukemia-free-survival [ Time Frame: 3 yrs ]
    Overall, progression-free and leukemia-free-survival.

  • Percent reduction in baseline biomarkers of angiogenesis including: circulating endothelial cells (CEC) and precursors (CEP), plasma and marrow VEGF and VEGFR 1-2 levels [ Time Frame: 3 yrs ]
    Percent reduction in baseline biomarkers of angiogenesis including: circulating endothelial cells (CEC) and precursors (CEP), plasma and marrow VEGF and VEGFR 1-2 levels.

  • Safety (type, frequency, severity, and relationship of adverse events to study therapy) [ Time Frame: 3 yrs ]
    Safety (type, frequency, severity, and relationship of adverse events to study therapy).

Enrollment: 20
Study Start Date: January 2008
Study Completion Date: December 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lenalidomide and Melphalan
Lenalidomide + Melphalan both given metronomically
Drug: Lenalidomide and melphalan
Lenalidomide (Revlimid) 10 mg po daily for 21d/28 Melphalan (Melphalan) 2 mg po daily for 21d/28
Other Names:
  • Revlimid
  • Melphalan

  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Understand and voluntarily sign an informed consent form.
  2. Age 18 years or older at the time of signing the informed consent form.
  3. Able to adhere to the study visit schedule and other protocol requirements.
  4. Must have a diagnosis of high-intermediate or high risk MDS (de novo or secondary) or CMML fitting any of the following classifications (including CMML with wbc < 12,000 x 109/L) and IPSS > 1.5 or proliferative form of CMML (wbc > 12,000 x 109/L for which the IPSS does not apply). If the patient has unsuccessful cytogenetics, patients with WHO classification of transfusion dependent RAEB-1 will be eligible (see appendix B and C for WHO MDS classification).
  5. All previous cancer therapy, including radiation, hormonal therapy and surgery, must have been discontinued at least 4 weeks (6 weeks for 5-Azacitidine or bone marrow transplant) prior to treatment in this study.
  6. ECOG performance status of <= 2 at study entry (see Appendix A).
  7. Laboratory test results within these ranges:

    • Serum calcium <3.0 mmol/L
    • Serum creatinine < 1.5 mg/dL
    • Total bilirubin < 1.5 mg/dL
    • AST (SGOT) and ALT (SGPT) < 2 x ULN

Exclusion Criteria:

  1. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
  2. Pregnant or breast-feeding females. (Lactating females must agree not to breast feed while taking lenalidomide).
  3. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
  4. Use of any other experimental drug or therapy within 28 days of baseline.
  5. Known hypersensitivity to thalidomide or melphalan.
  6. The development of erythema nodosum is characterized by a desquamating rash while taking thalidomide or similar drugs.
  7. Any prior use of lenalidomide.
  8. Concurrent use of other anti-cancer agents or treatments.
  9. Known positive for HIV or infectious hepatitis, types A, B or C.
  10. Must not have a diagnosis of AML (> 20% blasts) or other progressive malignant disease
  11. Must not have received treatment with, erythropoietin, or granulocyte colony-stimulating factors within seven days of study initiation (21 days for pegfilgrastim or Aranesp). Note: use of corticosteroids (topical and inhaled) is permitted and prophylactic steroids are allowed for transfusion reactions, but ongoing oral corticosteroids are not permitted.
  12. Serious or non-healing wound, ulcer, or bone fracture.
  13. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days of treatment.
  14. Any history of cerebrovascular accident (CVA) or transient ischemic attack within 12 months prior to study entry.
  15. Histories of myocardial infarction, cardiac arrhythmia, stable/unstable angina, symptomatic congestive heart failure, or coronary/peripheral artery bypass graft or stenting within 12 months prior to study entry.
  16. History of pulmonary embolism within the past 12 months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00744536

Canada, Ontario
Sunnybrook Health Sciences Centre, Odette Cancer Center
Toronto, Ontario, Canada, M4N3M5
Sponsors and Collaborators
Sunnybrook Health Sciences Centre
Principal Investigator: Rena J Buckstein, MD FRCPC Odette Cancer Center
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Dr. Rena Buckstein, Head Hematology Site Group, Sunnybrook Health Sciences Centre Identifier: NCT00744536     History of Changes
Other Study ID Numbers: RV-MDS-PI-128
Study First Received: August 29, 2008
Last Updated: June 8, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Dr. Rena Buckstein, Sunnybrook Health Sciences Centre:
Myelodysplastic syndrome
Chronic myelomonocytic leukemia
High intermediate risk and high risk IPSS score
Metronomic chemotherapy
Myelodysplastic Myeloproliferative Diseases

Additional relevant MeSH terms:
Myelodysplastic Syndromes
Leukemia, Myelomonocytic, Chronic
Pathologic Processes
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Leukemia, Myeloid
Neoplasms by Histologic Type
Myelodysplastic-Myeloproliferative Diseases
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents
Immunosuppressive Agents
Leprostatic Agents
Anti-Bacterial Agents
Anti-Infective Agents
Antineoplastic Agents, Alkylating
Alkylating Agents processed this record on August 22, 2017